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Abstract
Background: Cardiac CT angiography (CCTA) has become an important adjunct in the structural assessment of the
pulmonary veins (PV) prior to pulmonary vein isolation (PVI). Published data is conflicting regarding a relationship
between left atrial appendage (LAA) and the risk of ischemic stroke (CVA) following PVI. We investigated the
associations of volumetric and morphologic left atrial (LA) and LAA measurements for CVA following PVI.
Methods: We retrospectively reviewed 332 consecutive patients with drug refractory atrial fibrillation who obtained
cardiac CT angiogram (CCTA) prior to PVI. Baseline demographic data, procedural and lab details, and outcomes
were obtained from abstraction of an electronic medical records system. LA, LAA, and PV volumes were measured
using CCTA datasets utilizing a semi-automated 3D workstation application. LAA morphology was assigned utilizing
volume rendered images as previously described.
Results: The study cohort was 55 ± 13 years-old, 83.7% male, low CVA risk (median CHA2DS2Vasc 1; IQR 1, 3), and
30.4% were treated with novel oral anticoagulants. Chicken wing (CW) was the most common morphology (52%),
followed by windsock (WS), cauliflower (CF), and cactus (CS) at 18, 9, and 2%, respectively. CVAs occurred in 4
patients following PVI with median time to CVA of 170.5 days. All CVAs were observed in CW morphology patients.
When comparing CW morphology with non-CW morphology, CVAs occurred more frequently with the CW
morphology (2.1% vs 0%, p = 0.03). This difference was not significant, though, after adjusting for CHA2DS2Vasc
risk factors (p = 0.14).
Conclusion: The CW morphology was observed more commonly in patients who experienced post-PVI CVA. After
adjusting for CHA2DS2Vasc risk factors, CW morphology was not an independent predictor of post-PVI CVA. These
findings should be interpreted in the setting of a low CVA event rate amongst a low risk population that was
highly compliant with indicated anticoagulation therapy.
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Background
Atrial fibrillation (AF) is an increasingly prevalent dis-
ease with significant associated morbidity and mortality,
principally due to cerebral vascular accident (CVA) and
from symptomatic arrhythmia [1]. Pulmonary vein isola-
tion (PVI) continues to emerge as an effective treatment
for symptomatic AF [2, 3]. Cardiac CT angiography
(CCTA) has become an important adjunct in the structural
assessment of the pulmonary veins prior to PVI [4–6].
Additionally, the left atrial appendage (LAA), a common
nidus of thrombus formation in AF patients, is well visual-
ized and can be evaluated for the presence of thrombus in
appropriately protocoled studies [7–9]. Published data
suggests an association between LAA morphology, as de-
termined by CCTA, and risk for CVA in patients referred
for PVI [10]. In the largest of these studies, the chicken
wing (CW) morphology was 66% less likely to be present
in patients with a history of CVA, whereas the cactus
morphology was the highest risk LAA morphology [10].
The data on LAA morphology and predicting CVA follow-
ing PVI is less robust. We sought to determine CCTA-
derived factors associated with CVA in patients who




We identified 407 patients with drug-refractory atrial
fibrillation who underwent PVI between January 2008
and December 2014 at large military treatment facility.
Baseline demographic data, procedural and lab details,
and outcomes were obtained from manual chart abstrac-
tion of the electronic medical records (EMR). Patients
with incomplete or unavailable imaging data were
excluded from analysis (Fig. 1). Hypertension was de-
fined as previous diagnosis, currently taking any anti-
hypertensive medications, or a recorded systolic blood
pressure > 140 mm Hg on 2 separate encounters. Con-
gestive heart failure was defined as a previous diagnosis
based on review of past medical history. Diabetes melli-
tus was defined as a previous diagnosis based on EMR
review, currently taking any anti-hyperglycemic medica-
tions, or a most recent hemoglobin A1c value ≥ 6.5%.
Vascular disease was defined as any previous history of
myocardial infarction, coronary revascularization (percu-
taneous coronary intervention or coronary artery bypass
grafting), or peripheral arterial disease. CVA was identified
by EMR review and adjudicated utilizing the inpatient
EMR or assessment by an outpatient neurologist evalu-
ation. These risk factors, in addition to age and gender,
were used to calculate a CHA2DS2Vasc score [11]. Post-
PVI anticoagulation was recorded as the oral systemic
agent on which the patient was discharged following PVI.
Choice of oral systemic agent was at the discretion of the
electrophysiologist performing the PVI. Post-PVI CVA
events were identified utilizing the same criteria as
outlined above. Patients with TIA by ICD-9 code
listed following PVI were reviewed, but these in-
stances were excluded unless deemed by the investi-
gators to represent an embolic event. The vast
majority of patients underwent pre-procedural trans-
esophageal echocardiograph (89.5%) with finding of
possible thrombus in one patient. CCTA in this pa-
tient performed with early and delayed phases was
able to exclude thrombus. As the vast majority of
pre-procedural CCTAs were obtained with only a
Fig. 1 Flow chart depicting patient screening and reasons for exclusion from final analysis
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single, early phase, all patients with LAA filling de-
fects by CCTA were excluded from this analysis.
Pulmonary Vein Isolation (PVI)
All PVIs were performed utilizing bilateral femoral
venous access. For patients on warfarin therapy, this was
continued without bridging anticoagulation in the peri-
procedural period. In patients on NOACs leading up to
PVI, these medications were held for 24 h prior to the
procedure. Regardless of pre-procedural systemic anticoa-
gulation agent, intravenous heparin was administered with
a goal ACT of ≥350 s. ACT readings were reassessed at
30 min intervals and additional heparin boluses were
administered as needed while catheters were in the left
atrium. The esophagus was marked with a temperature
probe and intracardiac echocardiography (ICE) was
utilized for transseptal puncture. Transseptal puncture
was performed using Brockenbrough needle under fluoro-
scopic and ICE guidance. Left atrial access was confirmed
utilizing pressure transduction and saline administration.
A multipolar mapping catheter was placed into the left
atrium at operator discretion. Electroanatomic 3-D map-
ping of the left atrium was performed. Using contact force
mapping, lesions were placed in a circumferential manner
around the pulmonary veins. All ablation lesions were
performed utilizing an open-irrigated catheter ablation
system. The possibility of esophageal injury was mini-
mized by performing ablation at < 30 watts along the pos-
terior wall and terminating ablation with detected
temperature rise in the esophageal probe. All other abla-
tion lesions were performed utilizing 30–40 watts. Pacing
at the right superior pulmonary vein was performed to
confirm the absence of diaphragm stimulation prior to
ablation at operator’s discretion. A multi-polar mapping
catheter was then used to assess for any gaps. Immediate
post-ablation isolation of the pulmonary veins was con-
firmed by LA and PV pacing to ensure bidirectional block.
Non-PV triggers were induced utilizing isoproterenol and
additional radiofrequency ablations administered as indi-
cated. The ablation catheter was withdrawn to the right
atrium. Screening for pericardial effusion was performed
at the end of the case and pulmonary vein stenosis
excluded using ICE. All catheters were then removed and,
after reversal of anticoagulation with protamine, all sheaths
were removed. All patients, regardless of CHA2DS2Vasc
score, received 4 weeks of systemic anticoagulation (war-
farin or a NOAC) following PVI. Choice of anticoagulant
was at the discretion of the electrophysiologist performing
the PVI.
Cardiac computed tomography
From January of 2008 to March of 2011, images were
obtained using a retrospective ECG-gated acquisition
with a 64-slice CT scanner (Somatom Definition CT,
Siemens, Erlangen, Germany) reconstructed at 0.7 mm
slices centered on the 70% R-R interval. From March of
2011 to March of 2012, CCTA was performed utilizing a
prospective ECG-triggered acquisition centered on the 60
± 20% R-R interval. After March of 2012, a 128-slice dual-
source scanner (Somatom Definition Flash CT, Siemens,
Erlangen, Germany) utilizing prospective, ECG-triggered
acquisition centered on the 60 ± 20% R-R interval was
used. CCTA images were evaluated on a 3-dimension
workstation (Vital Images, Inc., Minnetonka, MN). Left
atrial (LA) and LAA parameters were obtained using elec-
trophysiology planning software package. Manual segmen-
tation of the LA and LAA was performed by delineating
the borders utilizing axial reconstructions. LAA volumes
were included in the LA volumes, however PV volumes
were excluded. The LAA os was pre-determined to be the
proximal border of the LAA and all visualized lobes were
included in the volumes. LAA morphology (Fig. 2) was
assigned by a single investigator (FK) based on review of
volume rendered reconstructions and reported as chicken
wing (CW), cauliflower (CF), cactus (CS), and windsock
(WS) as previously described [10]. The CW was defined
as a LAA morphology with a discrete bend in the prox-
imal to mid-portion of the dominant lobe, folding back
upon itself at some distance from the LAA ostium10. This
morphology could also contain secondary lobes or twigs.
The CF morphology was considered when LAA had a
limited overall length and more complex internal
characteristics. It was distinguished from other morpholo-
gies by variations in the ostium shape (oval vs round) and
a variable number of lobes without an identifiable do-
minant lobe [10]. The CS morphology was classified as a
Fig. 2 Volume rendered cardiac CT angiography images
demonstrating chicken wing (a), cauliflower (b), cactus (c), and
windsock (d) morphologies
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dominant central lobe and secondary lobes that extend in
both a superior and inferior direction [10]. Finally, the WS
morphology was defined as a dominant lobe of sufficient
length as the primary structure. Variations on this descrip-
tion to include different locations and numbers of smaller,
secondary or even tertiary lobes were included in this
morphologic group [10].
Statistical analysis
Statistical analysis was performed using IBM SPSS version
19.0 (IBM, Armonk, NY). Parametrically distributed con-
tinuous variables are reported as means with standard de-
viation and nonparametric data are reported as medians
with interquartile range. Comparison between continuous
variables was performed utilizing a Chi squared test or a
Wilcoxon Rank sum test, as appropriate. Cutoff values
with sensitivity and specificity were performed using a
receiver operator characteristics (ROC) curve. Multivari-
ate logistic regression was performed to assess for inde-
pendent CVA predictors. A Bonferroni correction was
applied when appropriate. A cutoff of p < 0.05 was used to
represent statistical significance. This research was carried
out with the approval of our local institutional review
board (IRB).
Results
The patient population of 332 individuals (mean age
55 ± 13 years, 83.7% male) were followed for median
of 72 months. Table 1 summarizes baseline demographic
data in patients with CW compared with non-CW LAA
morphology. No difference was observed in CHA2DS2-
Vasc scores between CW (median = 1 [IQR 1, 2]) and
non-CW (median = 2 [IQR 1, 4]) patients (p = 0.702).
Anticoagulation for CVA prophylaxis was achieved with a
novel oral anticoagulant in 30.4% of patients and warfarin
(pre-procedural INR 2.2 ± 0.5) in 69.6% (p < 0.001). There
was no difference observed between median proximate
INR in warfarin-treated patients (p = 0.432) and present-
ing rhythms (sinus rhythm, atrial arrhythmia, or paced)
prior to PVI were similar between CW and non-CW
patients.
The overall prevalence of post-PVl CVA was 1.2% (n = 4)
with median time to CVA of 170.5 days. In patients with
post-PVI CVA, the CHA2DS2Vasc score was zero in one
Table 1 Baseline demographic data in chicken wing (CW) morphology patients compared with non-CW patients. All continuous
variables are displayed as mean values ± standard deviation unless otherwise annotated
Total CW Non-CW p-value
(n = 332) (n = 190) (n = 142)
Age 55 ± 13 54 ± 13 56 ± 13 0.263
Age≥ 75 years 13 (15.2%) 5 (12.5%) 8 (5.6%) 0.490
Male gender 278 (83.7%) 160 (84.2%) 118 (83.1%) 0.785
HTN 200 (60.2%) 115 (60.5%) 85 (59.9%) 0.902
CHF 22 (6.6%) 14 (7.4%) 8 (5.6%) 0.518
DM2 48 (14.5%) 26 (13.7%) 22 (15.5%) 0.644
Vascular disease 140 (42.2%) 79 (41.6%) 61 (43.0%) 0.801
CHA2DS2Vasc > 1 162 (48.8%) 86 (45.3%) 76 (53.5%) 0.136
CHA2DS2Vasc, median (IQR) 1 (1, 3) 1 (1, 2) 2 (1, 4) 0.702
Prior CVA/TIA 16 (4.8%) 9 (4.7%) 7 (4.9%) 0.935
Post-PVI CVA 4 (1.2%) 4 (2.1%) 0 (0.0%) 0.034
Anticoagulation
Warfarin 201 (69.6%) 123 (73.7%) 78 (63.9%) 0.055
NOAC 88 (30.4%) 44 (26.3%) 44 (36.1%) 0.055
Aspirin 43 (13.0%) 23 (12.1%) 20 (14.1%) 0.589
Pre-procedure INRa 2.2 ± 0.5 2.2 ± 0.5 2.2 ± 0.5 0.432
Rhythm prior to PVI
Sinus rhythm 161 (48.8%) 88 (46.8%) 73 (51.4%) 0.407
Atrial Arrhythmia 166 (50.3%) 97 (51.6%) 69 (48.6%) 0.589
Paced 3 (0.9%) 3 (1.6%) 0 (0%) 0.131
Follow-up, mo., median (IQR) 72 (49, 97) 73 (49, 107) 69 (50, 92) 0.344
CW chicken wing, HTN hypertension, CHF congestive heart failure, DM2 diabetes mellitus, type 2, CVA cerebral vascular accident/stroke, TIA transient ischemic
attack, PVI pulmonary vein isolation, NOAC novel oral anticoagulant, INR international normalized ratio
aOnly includes patients treated with warfarin at the time of pulmonary vein isolation (PVI)
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patient, 1 in two patients, and 2 in the fourth patient.
Three patients were taking warfarin (one with a sub-
therapeutic INR at the time of CVA) and one patient was
treated with dabigatran. Post-PVI CVA was observed more
frequently in patients with CW morphology compared to
non-CW morphologies (2.1% vs 0%, p = 0.03). After adjust-
ing for known CVA risk factors, this difference no longer
met threshold for statistical significance (p = 0.14). There
was no difference between the groups with respect to the
prevalence of pre-PVI CVA (4.7% vs 4.9%, p = 0.935).
CHA2DS2Vasc score was predictive of pre-PVI CVA events
(AUC 0.799, p < 0.001), but was not discriminatory with re-
spect to predicting post-PVI CVA over 72 months of
follow-up (AUC 0.309, p = 0.188).
Measured LAA volumes, LA volumes, and average
Hounsfield unit (HU) attenuation values in CW and
non-CW morphologies are listed in Table 2. No difference
was observed between the absolute volume measures
between the groups, nor between volume and HU attenu-
ation ratios between the two groups. When comparing pa-
tients with post-PVI CVAs to the rest of the population
(Table 3), there was also no difference between LAA HU
attenuation or the ratio of LAA:LA HU attenuation as can
be seen in the setting of spontaneous echocontrast or
thrombus.
The prevalence of CW, WS, CF and CS morphologies
were 57.2, 25, 13.2 and 4.5%, respectively amongst post-
PVI patients in this population (Table 4). LAA volumes in
patients with CS morphology (9.5 ± 3.4 mL) differed sig-
nificantly from CW (13.6 ± 5.6 mL), WS (14.7 ± 6.4 mL),
and CF (14.7 ± 6.6 mL) morphologies (p = 0.011). Other
volumetric data did not differ between the groups.
Additionally, CVA risk factors and CHA2DS2Vasc scores >
1 were similar amongst the four LAA morphologies. Of
note, in this population with a low pre-PVI prevalence of
prior CVA, CW morphology was not associated with
lower observed rates of prior CVA.
Discussion
We observed an increased incidence of post-PVI CVA
in patients with CW morphology on CCTA, however
CW morphology was not found to be an independent
risk factor for post-PVI CVA after adjusting for
known CVA risk factors. Additionally, we did not find
any other volumetric or CT attenuation features of
the LAA or LA on pre-PVI CCTA that predicted
post-PVI CVA. The overall incidence of post-PVI
CVA was low in our population (1.2%), as was the
prevalence of patients with prior history of CVA prior
to PVI (4.7%). These data report on the largest cohort
of post-PVI patients to date on NOACs (30.4%) in
the lowest estimated CVA risk based on median
CHA2DS2Vasc score.
Table 2 Volumetric and CT attenuation data in chicken wing
(CW) morphology patients compared with non-CW patients
CT Characteristics Total CW Non-CW p-value
(n = 332) (n = 190) (n = 142)
LAA volume 13.8 ± 6.0 13.6 ± 5.6 14.1 ± 6.4 0.402
LA volume 99.5 ± 33.6 99.8 ± 34.5 99.2 ± 32.6 0.871
LAA/LA volume 0.145 ± 0.06 0.143 ± 0.05 0.148 ± 0.06 0.454
LAA HU 342.2 ± 77.9 340.2 ± 82.6 344.8 ± 71.5 0.599
LA HU 358.5 ± 96.8 363.6 ± 97.2 351.6 ± 96.2 0.265
LAA/LA HU 1.00 ± 0.36 0.97 ± 0.26 1.04 ± 0.47 0.065
LAA left atrial appendage, LA left atrium
All continuous variables are displayed as mean values ± standard deviation. All
volumes are displayed in milliliters (mL) and all CT attenuation numbers are
displayed in Hounsfield units (HU)
Table 3 Volumetric and CT attenuation data in patients with CVA
following PVI compared with patients without an observed event
CT Characteristics Post-PVI CVA No CVA after PVI p-value
(n = 4) (n = 328)
Age 58 ± 11 55 ± 13 0.655
Age≥ 75 years 0 (0%) 13 (4.0%) 0.682
Male gender 4 (100%) 274 (83.5%) 0.373
HTN 2 (50%) 198 (60.4%) 0.674
CHF 0 (0%) 22 (6.7%) 0.589
DM2 0 (0%) 48 (14.6%) 0.407
Vascular disease 1 (25%) 139 (42.4%) 0.484
Prior CVA/TIA 1 (25%) 15 (4.6%) 0.059
CHA2DS2Vasc > 1 1 (25%) 162 (49.4%) 0.332
CHA2DS2Vasc, median (IQR) 1 (0, 2.5) 1 (1, 3) 0.543
Anticoagulation
Warfarin 3 (75%) 198 (60.4%) 0.555
NOAC 1 (25%) 87 (26.5%) 0.952
Aspirin 0 (0%) 43 (13.1%) 0.435
Pre-procedure INR* 2.1 ± 0.3 2.2 ± 0.5 0.792
Rhythm prior to PVI
Sinus rhythm 1 (25%) 162 (49.4%) 0.332
Atrial Arrhythmia 2 (50%) 164 (50%) 1.000
Paced 1 (25%) 2 (0.6%) <0.001
LAA volume 13.9 ± 5.3 13.8 ± 6.0 0.989
LA volume 102.6 ± 18.3 99.5 ± 33.8 0.852
LAA/LA volume 0.13 ± 0.04 0.15 ± 0.06 0.655
LAA HU 372.4 ± 92.6 341.9 ± 77.8 0.438
LA HU 410.6 ± 78.8 357.8 ± 97.0 0.279
LAA/LA HU 0.90 ± 0.08 1.00 ± 0.36 0.594
LAA left atrial appendage, LA left atrium, CVA cerebral vascular accident/stroke,
PVI pulmonary vein isolation
All continuous variables are displayed as mean values ± standard deviation. All
volumes are displayed in milliliters (mL) and all CT attenuation numbers are
displayed in Hounsfield units (HU)
*INR only includes patients treated with coumadin prior to PVI
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The applications of CCTA, particularly as an adjunctive
modality in various EP procedures, have increased greatly
over the past decade. CCTA provides high-resolution, 3-
dimensional datasets that can be integrated into electro-
anatomic mapping systems utilized during PVI 5. CCTA
is also a complimentary modality in the evaluation of
LAA thrombus and has excellent sensitivity and negative
predictive power for excluding thrombus in appropriately
protocoled acquisitions [7–9]. Finally, CCTA may serve
an important role in the evaluation of the LAA in patients
referred for percutaneous LAA closure [12–14]. Prior to
the widespread availability and use of CCTA in the EP
realm, the LAA was described as a hooked tubular struc-
ture with a variable number of lobes. Distinct morphologic
features of LAA were first described in a population of pa-
tients undergoing PVI in which LAA morphology was
evaluated as a risk factor for a prior history of CVA [10].
The morphologies described were cactus (CS), cauliflower
(CF), chicken wing (CW) and windsock (WS) [10]. In this
initial analysis, patients with CW morphology were nearly
80% less likely to report a prior CVA (OR 0.21, 95% CI
0.05-0.91, p = 0.036). When compared to CW morph-
ology, there was an observed 8-fold increased risk of CVA
in patients with a CF morphology (p = 0.056). Subsequent
studies made similar observations regarding the CW
morphology as potentially protective with respect to CVA
risk while more complex morphologies (i.e. CS) portended
increased CVA risk [15–17]. These findings were codified
with the publication of a meta-analysis, which included
over 2,500 patients from eight studies [18]. Of note, 84%
of patients included in this analysis were at low overall
CVA risk as defined by a CHADS2 score < 2. CVA risk
was lowest amongst patients with CW morphology when
compared to non-CW patients (OR 0.46, 95% CI 0.36–
0.58, p < 0.001) [18]. Our data demonstrated similar re-
sults with the majority of prior CVA/TIA events being
identified in patients with a CF morphology. The low total
incidence of historical CVA/TIA in our patient population
likely explains why this difference did not reach statistical
significance.
Data evaluating the impact of LAA morphology on
post-PVI CVA is less robust. A single-center analysis of
2,570 consecutive patients undergoing PVI reported on
17 thromboembolic events (TE) within 30 days of PVI
and compared these patients to 68 propensity-matched
patients without peri-procedural TEs in a 1:4 ratio [19].
These authors observed a higher incidence of the CW
morphology amongst patients with TEs compared with
the matched control patients (65% vs 21%). Of note, the
median CHA2DS2Vasc score was 3 in both groups, the
median INR at the time of procedure was <2.0 in both
groups, and there was a numerically higher rate of peri-
procedural bridging with heparin in the TE group (82%
vs 69%, p = 0.278) [19]. In contrast, data on 2,069
patients enrolled in a German AF ablation registry found
no difference in TE risk between the different LAA
morphology groups [20]. TEs were observed in 15 pa-
tients (0.7% of the total population) during a 3.078 year
follow-up period [20]. The patient population in this
analysis was very similar in that the median CHA2DS2-
Vasc score was 3 and the vast majority of patients were
treated with warfarin. While INR values were not
reported in the event-free patients, mean discharge INR
in the TE group was 1.5 ± 0.5 and 2.37 ± 0.75 at the time
Table 4 Baseline demographic data, volumetric and CT attenuation data, and outcomes amongst all 4 LAA morphologies
Chicken Wing Cactus Windsock Cauliflower p-value
(n = 190) (n = 15) (n = 83) (n = 44)
LAA volume 13.6 ± 5.6 9.5 ± 3.4 14.7 ± 6.4 14.7 ± 6.6 0.011
LA volume 99.8 ± 34.5 101.8 ± 47.8 98.4 ± 29.3 99.7 ± 33.2 0.982
Total volume 145.2 ± 41.7 144.7 ± 53.2 145.5 ± 38.4 146.8 ± 40.5 0.996
Age 54 ± 13 54 ± 9 56 ± 12 56 ± 16 0.682
Age≥ 75 years 5 (2.6%) 0 (0%) 5 (6%) 3 (6.8%) 0.65
Male gender 147 (77.4%) 13 (86.7%) 77 (92.8%) 41 (93.2%) 0.954
HTN 115 (60.5%) 10 (66.7%) 53 (63.9%) 22 (50%) 0.45
CHF 14 (7.4%) 0 (0%) 4 (4.8%) 4 (9.1%) 0.549
DM2 26 (13.7%) 1 (6.7%) 16 (19.3%) 5 (11.4%) 0.436
Vascular disease 79 (41.6%) 6 (40%) 35 (42.2%) 20 (45.5%) 0.969
CHA2DS2Vasc > 1 86 (45.3%) 6 (40%) 48 (57.8%) 22 (50%) 0.246
Prior CVA/TIA 9 (4.7%) 0 (0%) 3 (3.6%) 4 (9.1%) 0.428
Post-PVI CVA 4 (2.1%) 0 (0%) 0 (0%) 0 (0%) 0.388
LAA left atrial appendage, LA left atrium, HTN hypertension, CHF congestive heart failure, DM2 diabetes mellitus, type 2, CVA cerebral vascular accident/stroke,
TIA transient ischemic attack, PVI pulmonary vein isolation
All volumes are displayed in milliliters (mL) and all CT attenuation numbers are displayed in Hounsfield units (HU)
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of event. Of note, very small proportions (5%) of patients
in this analysis were treated with NOACs for TE
prevention.
Our findings of a higher observed rate of CVA
amongst patients with CW morphology compared with
non-CW morphology is generally in agreement with pre-
viously published studies. While we did not find CW
morphology to be an independent risk factor, we believe
our analysis provides incremental data on the role LAA
anatomy may play on CVA/TE risk following PVI for
several reasons. The observed incidence of CVA in our
population was numerically higher (1.2%) but on par
with previous data in the setting of lower median
CHA2DS2Vasc scores. Additionally, NOACs were uti-
lized in 30.4% of patients in the peri-PVI period. Thus,
these data may be important as these agents continue to
be used more frequently by electrophysiologists around
the time of PVI. Finally, given this analysis was per-
formed in a single-payer managed healthcare system
where patients have ready access to warfarin or NOACs
at no direct cost, compliance with anticoagulation ther-
apy may be higher. Thus, despite low estimated CVA
risk and readily available access to anticoagulant medica-
tions, there was a numerically higher incidence of CVA
in this population suggesting that additional factors be-
yond the traditional CHA2DS2Vasc factors and adequate
anticoagulation may be important in identifying at-risk
patients. Further studies utilizing a multi-modality im-
aging approach to TE/CVA risk assessment following
PVI may be warranted in order to determine whether
morphology, when added to other proposed risk factors
such as LAA orifice size, degree of LAA trabeculations,
LA ejection fraction (EF), LAA peak velocity, and LAA
EF, may identify high post-PVI risk patients with low
CHA2DS2Vasc scores [17, 21, 22].
Limitation
This analysis is limited by its retrospective design and
the fact that the patient population is derived from a
single-center, tertiary care facility. Overall event rates for
post-PVI CVA and prior CVA were low, likely reflecting
the relatively low CVA risk of the population based on
CHA2DS2Vasc score, high compliance, and easy access
to appropriate anticoagulant therapies. We were unable to
determine post-PVI recurrence rates of atrial dysrhythmia,
which represents an additional risk factor to CVA in this
population. Procedural duration, as a surrogate for the ex-
tent of ablation, was not routinely reported in the EMR,
thus any association between post-procedural outcomes
and the extent of ablation could not be investigated.
Additionally, we did not perform an analysis of intra- and
inter-observer variability, thus it is possible that LAA
morphologies were incorrectly allocated. Previously
published data has reported very good agreement in
distinguishing CW from non-CW morphology by experi-
enced readers in high-volume centers by CCT (kappa =
0.96, p < 0.001) [10]. Applicability of these findings to a
general population and comparison to prior studies in this
field is limited given the predominately male cohort,
younger median age, and the variable post-PVI anticoagu-
lants utilized.
Conclusions
The CW morphology was observed more commonly in
patients who experienced post-PVI CVA. After adjusting
for CVA risk factors, CW morphology was not an inde-
pendent predictor of post-PVI CVA. These findings
should be interpreted in the setting of a low CVA event
rate amongst a low risk population that was highly com-
pliant with indicated anticoagulation therapy.
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